Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.48 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.41 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.41 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.41 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5287968 | 0.82 | MAPT (0.44) | RIPK1ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL21313898 | 0.78 | RIPK1 (0.52) | CTBP2RIPK1KIF11PKMALDH1A1 | |
| SCHEMBL5925967 | 0.77 | PNMT (0.47) | RIPK1ALDH1A1KMT2AMEN1PNMT | |
| SCHEMBL28100713 | 0.76 | PKM (0.48) | CTBP2RIPK1KIF11PKMALDH1A1 | |
| SCHEMBL3476733 | 0.76 | RIPK1 (0.54) | CTBP2RIPK1KIF11PKMMAOA | |
| SCHEMBL5790565 | 0.75 | CTBP2 (0.67) | CTBP2ERCC5FEN1PLAAT3PLAAT5 | |
| SCHEMBL11974009 | 0.75 | RIPK1 (0.49) | CTBP2RIPK1PNMT | |
| SCHEMBL6585765 | 0.75 | ERCC5 (0.47) | CTBP2ERCC5FEN1RIPK1KIF11 | |
| SCHEMBL6340256 | 0.75 | BLM (0.58) | CTBP2RIPK1KIF11PKMALDH1A1 | |
| SCHEMBL4340077 | 0.75 | BLM (0.58) | CTBP2RIPK1KIF11PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101146773-A | 6, 7, 8, 9-tetrahydro-5-amino-5h-benzocyclohepten-6-ol derivatives and related compounds used as anti-inflammatory agents | BAYER SCHERING PHARMA AG (DE) | 2008-03-19 | — | — | CN | disclosed |
| EP-1863765-A1 | 6, 7, 8, 9-TETRAHYDRO-5-AMINO-5H-BENZOCYCLOHEPTEN-6-OL DERIVATIVES AND RELATED COMPOUNDS USED AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-20060247292-A1 | Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
| WO-2006100099-A1 | 6, 7, 8, 9-TETRAHYDRO-5-AMINO-5H-BENZOCYCLOHEPTEN-6-OL DERIVATIVES AND RELATED COMPOUNDS USED AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247292-A1 | Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents | TNF, NFKBIA, PTGES | CTBP2 1981/4885ERCC5 3592/4885FEN1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.